Inhaled insulins
- PMID: 17344572
- PMCID: PMC2599981
- DOI: 10.1136/pgmj.2006.053868
Inhaled insulins
Abstract
As a result of knowledge gained from the management of asthma with inhalers and nebulisers, pulmonary delivery devices for insulin have been developed. Particle size of the aerosol particularly influences drug delivery. Although several pharmaceutical companies are developing different systems, Pfizer have launched the first inhaled insulin (Exubera). Clinical trials have taken place in patients with both type 1 and type 2 diabetes, but have shown similar glucose control as subcutaneous insulin delivery. However, patient satisfaction does seem to be increased in patients taking inhaled insulins. Further studies are needed to investigate compliance, side-effect profiles, quality of life, long-term glycaemia control and cost effectiveness.
Conflict of interest statement
Competing interests: None.
References
-
- Cefalu W T. Evolving strategies for insulin delivery and therapy. Drugs 2004641149–1161. - PubMed
-
- Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 200171327–1351. - PubMed
-
- American Diabetes Association Standards of Medical Care in Diabetes–2006. Clinical practice reccomendations 200629(Suppl 1)S10 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials